MSB Logo 2022.jpg
Appendix 4C Quarterly Activity Report
April 28, 2022 20:35 ET | Mesoblast Limited
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
MSB Logo 2022.jpg
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
March 23, 2022 20:40 ET | Mesoblast Limited
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R....
Operational Highlights and Financial Results for the Period Ended December 31, 2021
February 24, 2022 17:30 ET | Mesoblast Limited
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
MSB Logo 2022.jpg
Mesoblast Corporate Update and Financial Results Webcast
February 24, 2022 05:57 ET | Mesoblast Limited
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
MSB_logo_notag (001).jpg
Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy
February 20, 2022 18:19 ET | Mesoblast Limited
NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from...
MSB_logo_notag (001).jpg
Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer
February 01, 2022 19:20 ET | Mesoblast Limited
NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment...
MSB_logo_notag (001).jpg
Appendix 4C Quarterly Activity Report
January 30, 2022 19:16 ET | Mesoblast Limited
NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational and...
MSB_logo_notag (001).jpg
Mesoblast to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022
January 24, 2022 18:45 ET | Mesoblast Limited
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it is participating in...
MSB_logo_notag (001).jpg
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease
January 11, 2022 20:26 ET | Mesoblast Limited
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced 36-month follow-up...
MSB_logo_notag (001).jpg
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease
December 30, 2021 18:38 ET | Mesoblast Limited
Key Points: Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) to address potency assay and chemistry, manufacturing and controls (CMC)...